Search results for: Determining Value
Filter search results
Anchoring Latent Scale Values for the EQ-5D-Y at 0 = Dead
20 January 2020
…of the EQ-5D patient-reported outcomes measure) in cost-utility analysis. Discrete choice experiments (DCEs) can be used to obtain values on a latent scale, but these values require anchoring at = dead to meet the conventions…
Cost-effectiveness Analysis of Gene Therapies for Inherited Eye Disease: Are Current Discounting Approaches Too Short-sighted?
15 February 2023
…a result, an intervention which generates health equivalent to the value of £100 this year will be prioritised over an intervention which generates health equivalent to the value of £100…
NICE’s Social Value Judgments: A Closer Look at Progress
30 May 2012
…article provides a brief overview of why NICE has implemented a policy of transparency for social value judgments, and why its social value judgments about cost-effectiveness are more specific than…
Spotlight on OHE: Understanding Value Based Pricing
12 February 2013
Value based pricing (VBP) is increasingly common in health care systems worldwide. OHE continues to make important contributions to the debate about VBP approaches and application through its research, publications…
Financing and Scaling Innovation for the COVID Fight: A Closer Look at Demand-Side Incentives for a Vaccine
1 April 2020
…for supply; two models (cost- or value-based), with countries pre-committing to purchases meeting specified efficacy. The authors prefer a value-based model. A CGD Note published on the Center for Global…
The BRAVE Initiative: The BRAVE Narrative for Broad Recognition of Value in Vaccines Engagement
1 September 2020
…OHE is undertaking a research programme called the Broad Assessment of Value in Vaccines (BRAVE) Initiative. The BRAVE- Initiative aims to increase recognition of the broader value elements of vaccines…
Breaking the European Deadlock: Part 2 – Transferable Exclusivity Vouchers – Effective Pull Incentive or a Policy Distraction?
4 January 2024
…there could be enormous variability in the value of the TEV depending on the sales value of the products reaching the end of their patent life or data exclusivity period….
OHE at ISPOR May 2016: Meet the Team
19 May 2016
…the patient of having greater certainty of treatment benefit. The Paper also identifies several other sources of value related to information, including real option value, the value of hope, insurance…
Eliciting the Relative Value of Life Extension at the End of Life
29 November 2016
…Discussion of presentation by Rachel Baker Perspectives, priorities and plurality Eliciting societal values and the relative value of life extension at the end of life from Office of Health Economics…